

Maarten J Titulaer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2889830/maarten-j-titulaer-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

102
papers

11,694
citations

47
h-index

108
g-index

108
ext. papers

14,337
ext. citations

8.8
avg, IF

6.08
L-index

#	Paper	IF	Citations
102	Antibody Therapies in Autoimmune Encephalitis.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	2
101	Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	11
100	Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 757-768	5.5	50
99	Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	59
98	Encephalitis with Autoantibodies against the Glutamate Kainate Receptors GluK2. <i>Annals of Neurology</i> , 2021 , 90, 101-117	9.4	8
97	Autoimmune Neurology: The Need for Comprehensive Care. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
96	The association between systemic autoimmune disorders and epilepsy and its clinical implications. <i>Brain</i> , 2021 , 144, 372-390	11.2	5
95	Treatment Approaches in Autoimmune Neurology: Focus on Autoimmune Encephalitis with Neuronal Cell Surface Antibodies 2021 , 261-278		1
94	No Evidence for the Involvement of Leiomodoin-1 Antibodies in the Pathogenesis of Onchocerciasis-Associated Epilepsy. <i>Pathogens</i> , 2021 , 10,	4.5	3
93	Autoimmune Encephalitis Resembling Dementia Syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	7
92	Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. <i>Neurology</i> , 2021 ,	6.5	13
91	Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab145	0.9	1
90	The role of antibody indexes in clinical virology. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1207-1211	9.5	3
89	Antibodies Contributing to Focal Epilepsy Signs and Symptoms Score. <i>Annals of Neurology</i> , 2021 , 89, 698-710	9.4	15
88	Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	46
87	Pediatric autoimmune encephalitis: Recognition and diagnosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	18
86	Autoimmune psychosis. <i>Lancet Psychiatry</i> , 2020 , 7, 122-123	23.3	5

85	Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. <i>Neurology</i> , 2020 , 94, e511-e520	6.5	11
84	Absence of Autoantibodies Against Neuronal Surface Antigens in Sera of Patients With Psychotic Disorders. <i>JAMA Psychiatry</i> , 2020 , 77, 322-325	14.5	7
83	Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. <i>Neurology</i> , 2020 , 95, e3012-e3025	6.5	27
82	Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambert-Eaton myasthenic syndrome. <i>Muscle and Nerve</i> , 2020 , 62, 111-114	3.4	3
81	The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. <i>Brain</i> , 2019 , 142, 1631-1643	11.2	43
80	Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABAR encephalitis. <i>Neurology</i> , 2019 , 92, e2185-e2196	6.5	112
79	An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. <i>Lancet Neurology</i> , 2019 , 18, 1045-1057	24.1	231
78	Intracranial actinomycosis of odontogenic origin masquerading as auto-immune orbital myositis: a fatal case and review of the literature. <i>BMC Infectious Diseases</i> , 2019 , 19, 763	4	4
77	Cerebellar ataxia as a presenting symptom in a patient with anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019 , 6, e579	9.1	7
76	A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. <i>Neurology</i> , 2019 , 92, e244-e252	6.5	101
75	The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders. <i>Journal of Neuroimmunology</i> , 2019 , 326, 14-18	3.5	8
74	Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis. <i>Neurology</i> , 2018 , 90, e1997-e2005	6.5	58
73	Predictive value of electroencephalography in anti-NMDA receptor encephalitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 1101-1106	5.5	38
72	No neuronal autoantibodies detected in plasma of patients with a bipolar I disorder. <i>Psychiatry Research</i> , 2018 , 259, 460-462	9.9	2
71	Nodding syndrome: Preventable and treatable. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	19
70	Serum neuronal cell-surface antibodies in first-episode psychosis. <i>Lancet Psychiatry</i> , 2017 , 4, 186-187	23.3	6
69	DPPX antibody-associated encephalitis: Main syndrome and antibody effects. <i>Neurology</i> , 2017 , 88, 1340-1348	108	
68	The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. <i>Nature Reviews Neurology</i> , 2017 , 13, 290-301	15	129

67	Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies). <i>Current Opinion in Neurology</i> , 2017 , 30, 302-309	7.1	40
66	Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4. <i>Annals of Neurology</i> , 2017 , 81, 193-198	9.4	86
65	Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes. <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 680-686	5.3	18
64	Innate and adaptive immunity in human epilepsies. <i>Epilepsia</i> , 2017 , 58 Suppl 3, 57-68	6.4	40
63	The clinical spectrum of Caspr2 antibody-associated disease. <i>Neurology</i> , 2016 , 87, 521-8	6.5	233
62	Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity. <i>Annals of Neurology</i> , 2016 , 80, 388-400	9.4	95
61	The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. <i>Neurology</i> , 2016 , 87, 1848-1849	6.5	96
60	A clinical approach to diagnosis of autoimmune encephalitis. <i>Lancet Neurology</i> , 2016 , 15, 391-404	24.1	1774
59	Prevalence of Intrathecal Acyclovir Resistant Virus in Herpes Simplex Encephalitis Patients. <i>PLoS ONE</i> , 2016 , 11, e0155531	3.7	15
58	Detection and Characterization of Autoantibodies to Neuronal Cell-Surface Antigens in the Central Nervous System. <i>Frontiers in Molecular Neuroscience</i> , 2016 , 9, 37	6.1	18
57	The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. <i>Neurology</i> , 2016 , 86, 1692-9	6.9	117
56	Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder. <i>JAMA Neurology</i> , 2016 , 73, 714-20	17.2	101
55	Anti-NMDAR encephalitis and other glutamate and GABA receptor antibody encephalopathies. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 133, 199-217	3	11
54	Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. <i>Neurology</i> , 2016 , 87, 1449-1456	6.5	286
53	From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over time. <i>Autoimmunity Reviews</i> , 2016 , 15, 970-4	13.6	67
52	Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. <i>Neurology</i> , 2015 , 84, 2403-12	6.5	232
51	Autoimmune Encephalitis in Postpartum Psychosis. <i>American Journal of Psychiatry</i> , 2015 , 172, 901-8	11.9	65
50	Absence of N-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia: The Importance of Cross-Validation Studies. <i>JAMA Psychiatry</i> , 2015 , 72, 731-3	14.5	54

49	Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. <i>Brain</i> , 2015 , 138, 94-109	11.2	289
48	Transient anti-NMDAR encephalitis in a newborn infant due to transplacental transmission. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e126	9.1	18
47	Pathologically confirmed autoimmune encephalitis in suspected Creutzfeldt-Jakob disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e178	9.1	29
46	Early recognition of anti-N-methyl-D-aspartate receptor encephalitis in psychiatric patients. <i>Acta Psychiatrica Scandinavica</i> , 2015 , 132, 312-3	6.5	3
45	Autoimmune Encephalitis 2015 , 247-276		
44	Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response. <i>JAMA Neurology</i> , 2015 , 72, 180-6	17.2	106
43	Plasticity-related gene 5: A novel surface autoantigen in paraneoplastic cerebellar degeneration. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e156	9.1	9
42	Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. <i>Lancet Neurology</i> , 2014 , 13, 276-86	24.1	413
41	Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system. <i>Autoimmunity Reviews</i> , 2014 , 13, 299-312	13.6	47
40	Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. <i>Annals of Neurology</i> , 2014 , 75, 411-28	9.4	302
39	Herpes simplex virus encephalitis is a trigger of brain autoimmunity. <i>Annals of Neurology</i> , 2014 , 75, 317-23	9.4	290
38	Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. <i>Lancet Neurology</i> , 2014 , 13, 167-77	24.1	582
37	A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. <i>Annals of Neurology</i> , 2014 , 75, 435-41	9.4	40
36	Reply: To PMID 24700511. <i>Annals of Neurology</i> , 2014 , 76, 464-5	9.4	
35	Cortactin autoantibodies in myasthenia gravis. <i>Autoimmunity Reviews</i> , 2014 , 13, 1003-7	13.6	79
34	Determination of neuronal antibodies in suspected and definite Creutzfeldt-Jakob disease. <i>JAMA Neurology</i> , 2014 , 71, 74-8	17.2	43
33	The Lambert-Eaton Myasthenic Syndrome 2014 , 189-204		
32	Treatment options for LambertEaton myasthenic syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 159-167	1.1	

31	Anti-N-methyl-D-aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of the literature. <i>Pediatric Neurology</i> , 2014 , 50, 181-4	2.9	57
30	Lambert-Eaton Myasthenic Syndrome 2014 , 1089-1099		
29	Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. <i>JAMA Neurology</i> , 2013 , 70, 1133-9	17.2	274
28	AuthorsTreply. <i>Lancet Neurology, The</i> , 2013 , 12, 425-6	24.1	31
27	Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. <i>Lancet Neurology, The</i> , 2013 , 12, 157-65	24.1	1788
26	Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome. <i>Human Immunology</i> , 2013 , 74, 849-51	2.3	8
25	Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. <i>Journal of Pediatrics</i> , 2013 , 162, 850-856.e2	3.6	303
24	Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia. <i>Current Treatment Options in Neurology</i> , 2013 , 15, 224-39	4.4	22
23	Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. <i>Neurology</i> , 2013 , 81, 1637-9	6.5	137
22	Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. <i>Neurology</i> , 2013 , 81, 1500-6	6.5	312
21	Late-onset anti-NMDA receptor encephalitis. <i>Neurology</i> , 2013 , 81, 1058-63	6.5	134
20	Risk for myasthenia gravis maps to a (151) Pro-Ala change in TNIP1 and to human leukocyte antigen-B*08. <i>Annals of Neurology</i> , 2012 , 72, 927-35	9.4	112
19	Paraneoplastic syndromes and autoimmune encephalitis: Five new things. <i>Neurology: Clinical Practice</i> , 2012 , 2, 215-223	1.7	52
18	SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2012 , 1275, 70-7	6.5	14
17	1600 The utility of SOX antibodies for cancer prediction in patients with paraneoplastic neurological disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, e1.135-e1	5.5	
16	IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. <i>Journal of Proteome Research</i> , 2011 , 10, 143-52	5.6	70
15	Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. <i>European Journal of Neurology</i> , 2011 , 18, 19-e3	6	332
14	Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. <i>Lancet Neurology, The</i> , 2011 , 10, 1098-107	24.1	241

13	Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. <i>Journal of Clinical Oncology</i> , 2011 , 29, 902-8 ^{2.2}	114
12	A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. <i>Brain</i> , 2011 , 134, 3167-75	11.2 125
11	Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. <i>Neurology</i> , 2011 , 77, 1698-701 ⁵	260
10	3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. <i>Expert Review of Clinical Immunology</i> , 2010 , 6, 867-74	5.1 24
9	SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4260-7	2.2 144
8	Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 86, 44-8	6.1 94
7	The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. <i>Journal of Neuroimmunology</i> , 2008 , 201-202, 153-8	3.5 87
6	Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. <i>Journal of Neuroimmunology</i> , 2008 , 204, 136-9	3.5 24
5	Re: Lambert-Eaton myasthenic syndrome with pure ocular weakness. <i>Neurology</i> , 2008 , 70, 86; author reply 86-7	6.5 8
4	Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4276-81	2.2 94
3	Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. <i>Annals of the New York Academy of Sciences</i> , 2008 , 1132, 129-34	6.5 58
2	Available treatment options for the management of Lambert-Eaton myasthenic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1323-36	4 38
1	Screening for Tumours in Paraneoplastic Syndromes309-320	1